United States: Drug Quality And Security Act: What You Need To Know

Last Updated: December 9 2013
Article by Mary C. DeBartolo, Stephanie A. Kennan and Brian J. Looser

In recent years, Congress and the Food and Drug Administration (FDA) have worked on several legislative measures designed to address weaknesses in the U.S. drug supply. In response to the fungal meningitis outbreak linked to unsanitary conditions at a compounding pharmacy in the Fall of 2012 as well as concerns regarding counterfeit, falsified, substandard and dangerous prescription medication, Congress has voted on several measures. Specifically, the Senate Committee on Health Education, Labor and Pensions (HELP) reported S. 959, the Pharmaceutical Quality, Security, and Accountability Act, legislation aimed at enhancing the regulatory structure for compounded medications. The House of Representatives passed H. R. 1919, Safeguarding America's Pharmaceuticals Act of 2013, which constituted the House of Representatives's endeavor to create a more secure drug delivery system. Ultimately, the House and Senate agreed to combine compounding and supply chain security legislation into one proposal and passed H.R. 3204, the Drug Quality and Security Act.

The Drug Quality and Security Act has two distinct and independent acts: 1) the Compounding Quality Act and 2) the Drug Supply Chain Security Act. The Compounding Quality Act creates a voluntary compliance regime where compounding pharmacies that voluntarily register as "outsourcing facilities" will be subject to oversight by the FDA in much of the same way that traditional pharmaceutical manufacturers are monitored. The Drug Supply Chain Security Act requires the FDA to create and implement a national track-and-trace system by which manufacturers must affix product identifiers (bar codes) that are either human-readable or machine-readable to each package or homogenous case of a pharmaceutical product intended to be introduced into the supply chain. President Obama signed the bill into law on Nov. 27, 2013. On Dec. 2, FDA held a press briefing and released several documents regarding the implementation of the Drug Quality and Security Act, and more specifically, the Compounding Quality Act.

Below is an overview of the legislative history, implementation requirements and outstanding issues relevant to each individual act within the Drug Quality and Security Act.

Compounding Quality Act

This legislation represents Congress's response to the tainted injectable drugs from New England Compounding Center (NECC) in Massachusetts, which caused an outbreak of fungal meningitis resulting in 64 deaths and over 750 cases of fungal meningitis in 20 states. Prior to the passage of the Drug Quality and Security Act, FDA had limited oversight over compounding pharmacies, which were traditionally regulated at the state level. At the same time, a distinct difference had developed among compounding pharmacies: those that compound in small quantities for a local area and those that mass produce compounded medications for sale throughout the United States. The Drug Quality and Security Act, through the Compounding Quality Act, attempts to distinguish between the small compounder and mass-producing compounding pharmacies but will need the support of market forces to be successful.

Outsourcing Facilities

The Compounding Quality Act defines a new type of compounding pharmacy — an "outsourcing facility." An outsourcing facility is a facility at one geographic location that is engaged in compounding sterile drugs, has elected to register as an outsourcing facility with the FDA and is subject to certain compounding constraints and inspection requirements. A list of facilities registered as outsourcing facilities will be publically available on the FDA website.

Outsourcing facilities will have to register themselves and the products they compound with the FDA. The FDA will collect an establishment fee when the outsourcing facility registers with the FDA. The initial base registration fee is $15,000, subject to adjustment for inflation and small businesses. The FDA may also collect reinspection fees from outsourcing facilities. Further, outsourcing facilities must label their products with a statement that identifies the drug as a compounded drug and other enumerated requirements, including the contact information of the outsourcing facility, the lot number, the date the drug was compounded and the expiration date, storage and handling instructions, a statement that the drug is "not for resale," and a list of active and inactive ingredients. The FDA will also receive adverse event reports from the outsourcing facilities and be able to conduct risk-based inspections at the outsourcing facilities. Risk-based inspections will be based on factors including the compliance history of the outsourcing facility; the record, history and nature of recalls linked to the outsourcing facility; and the inherent risk of the drugs compounded at the outsourcing facility.

The legislation also requires the GAO to report within 36 months of the passage of the Drug Quality and Security Act on the effectiveness of both the state and federal efforts to assure the safety of compounded drugs and the availability of tools to permit purchasers of compounded drugs to determine the safety and quality of such drugs.

Registration Concerns

The main looming issue with regard to the Compounding Quality Act is, how effective will the voluntary registration system be? Analysts argue that market forces will cause larger compounders to register as outsourcing facilities. The analysts reason that hospitals and other providers will require that compounders be registered as outsourcing facilities and subject to FDA inspection requirements, quality standards and adverse event reporting.

In the Dec. 2 press conference and in an FDA blog post by FDA Commissioner Hamburg, FDA publically encouraged healthcare providers and health networks to purchase products from FDA-registered outsourcing facilities. Other analysts, however, argue that the voluntary registration requirement is a loophole. All the while, the International Academy of Compounding Pharmacists (IACP) maintains that the law contains many "unknowns" that are detrimental to the practice of pharmacy.

However, stakeholders will have an opportunity to weigh in on the promulgation of regulations to formally implement the legislation. For example, FDA announced it is starting to develop lists of drugs that cannot be compounded and of bulk ingredients that can be used in compounding, as required by the Drug Quality and Safety Act. To identify candidates for these lists, FDA is encouraging interested groups and individuals to nominate specific drug products or categories of drug products and is describing the information that should be provided to the agency in support of each nomination. In addition, the agency has promised to work with policymakers and industry to develop a workable framework for "office use" allowances of compounded medications done without a prescription or identified patient, as certain commonly compounded products are kept on hand by medical professionals.

Drug Supply Chain Security Act

For several years, policymakers have explored and attempted to improve the security of the drug supply chain, in part, to prevent the introduction of unsafe elements. For example, in 2012, legislation to reauthorize prescription drug and device user fee programs included language that would have created a national drug "track-and-trace system," but it was not included in the final bill. The second part of the Drug Quality and Security Act formally establishes a national pharmaceutical track and trace system.

Pre-emption of State Law

The track-and-trace system required by the Drug Supply Chain Security Act will replace the currently fragmented system of product tracing with a uniform, electronic and interoperable unit-level product tracing system. Important to the pharmaceutical industry is the explicit preemption of California's e-pedigree requirements, which would have come into effect in 2015. The legislation states that no state or political subdivision of a state may establish or continue in effect any requirements for tracing products through the distribution system that are inconsistent with, more stringent than or in addition to any of the requirements under the Drug Supply Chain Security Act.

Implementation Issues

The track-and-trace system would be implemented throughout the next decade and would track a product down to the package level. Similar to the recently finalized unique device identifier (UDI) rule for medical devices, the legislation would establish nationwide drug serial numbers. The aim of the nationwide drug serial numbers is to allow for efficient tracing to respond to recalls and notices of theft and counterfeiting.

Within one year after the passage of the Drug Quality and Security Act, FDA is required to issue a draft guidance document that establishes standards for the interoperable exchange of pharmaceutical tracking information in either paper or electronic format. In establishing the guidance, the secretary must allow for a public notice and comment period.

No later than two years after the date of enactment, FDA must issue further guidance discussing how a participant in the pharmaceutical supply chain may request a waiver or exception or be exempt from reporting requirements. This guidance must be reviewed biennially to determine whether the waivers, exceptions and exemptions are still applicable. During the same time period, FDA must also identify circumstances under which a product is grandfathered and exempt from the new law's requirements.

During the initial implementation years, FDA will establish and coordinate pilot projects with manufacturers, repackagers, wholesale distributors, dispensers and other parties to explore and evaluate methods to enhance the safety and security of the pharmaceutical distribution supply chain.

Starting Jan. 1, 2015, manufacturers will be required to capture the transaction history and movement of a pharmaceutical product through the supply chain and store the information for at least six years. Initially, manufacturers will be able to store the information in either paper or electronic format, but eventually, manufacturers will be required to store the information in electronic format. At the same time, certain other participants in the pharmaceutical supply chain, including wholesale distributors, dispensers and repackagers, must develop verification methods to determine whether a product is a valid, suspect or illegitimate product. Upon determining it is in possession of such a product, a participant in the secure drug supply chain must notify its trading partners in order to prevent further circulation of potentially compromised medication. Authorized participants in the drug supply chain must also respond within 48 hours to requests from appropriate federal or state officials — in the event of a recall or for the purpose of investigating a suspect product or an illegitimate product — for the transaction history of the pharmaceutical product. .

The overall goal is to establish, within 10 years from the date of enactment of the Drug Quality and Security Act, an interoperable, electronic tracing system of pharmaceutical products, down to the package level, that is able to promptly respond in the event of a recall or for the purposes of investigating a suspect product or an illegitimate product.

Overall, the structure and effectiveness of the track-and-trace system remain to be seen. In conjunction with the implementation of the UDI requirements, questions remain about how the system will technically perform.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.